SUN-LB080 ACROSTUDY - Safety and Efficacy of a Cohort of 110 Naïve Patients with Acromegaly Treated with Pegvisomant

Background:  ACROSTUDY is an open-label, non-interventional post-authorization safety study that began in 2004 to evaluate safety in at least 1000 acromegaly patients treated with the GH receptor antagonist pegvisomant (PEGV).  This commitment was fulfilled in Jan 2013. ACROSTUDY w...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Endocr Soc
Autores principales: Wajnrajch, Michael, Gomez, Roy, Hey-Hadavi, Judith, Kelepouris, Nicky, Lans, Joli, Loftus, Jane, Camacho-Hubner, Cecilia, Cara, Jose, Rao Valluri, Srinivas, Fleseriu, Maria, Salvatori, Roberto, Webb, Susan, Brue, Thierry, Palladino, Andrew
Formato: Artigo
Lenguaje:Inglês
Publicado: Endocrine Society 2019
Materias:
Neuroendocrinology and Pituitary
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6553204/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-LB080
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares